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The striatum is composed principally of GABAergic, medium spiny striatal projection neu-
rons (MSNs) that can be categorized based on their gene expression, electrophysiological
proﬁles, and input–output circuits. Major subdivisions ofMSN populations include (1) those
in ventromedial and dorsolateral striatal regions, (2) those giving rise to the direct and indi-
rect pathways, and (3) those that lie in the striosome and matrix compartments. The ﬁrst
two classiﬁcatory schemes have enabled advances in understanding of how basal ganglia
circuits contribute to disease. However, despite the large number of molecules that are
differentially expressed in the striosomes or the extra-striosomal matrix, and the evidence
that these compartments have different input–output connections, our understanding of
how this compartmentalization contributes to striatal function is still not clear. A broad view
is that the matrix contains the direct and indirect pathwayMSNs that form parts of sensori-
motor and associative circuits, whereas striosomes contain MSNs that receive input from
parts of limbic cortex and project directly or indirectly to the dopamine-containing neurons
of the substantia nigra, pars compacta. Striosomes are widely distributed within the stria-
tum and are thought to exert global, as well as local, inﬂuences on striatal processing by
exchanging information with the surrounding matrix, including through interneurons that
send processes into both compartments. It has been suggested that striosomes exert and
maintain limbic control over behaviors driven by surrounding sensorimotor and associative
parts of the striatal matrix. Consistent with this possibility, imbalances between striosome
and matrix functions have been reported in relation to neurological disorders, including
Huntington’s disease, L-DOPA-induced dyskinesias, dystonia, and drug addiction. Here,
we consider how signaling imbalances between the striosomes and matrix might relate to
symptomatology in these disorders.
Keywords: striatum, medium spiny neuron, Huntington’s disease, Parkinson’s disease, dystonia, dyskinesia,
substantia nigra, CalDAG-GEF
INTRODUCTION
The striatum is the primary input side of the basal ganglia, a set
of subcortical brain regions that are important for the control of
voluntary movement and our ability to learn patterns of behavior
that maximize reward. The striatum integrates incoming infor-
mation from all regions of the cerebral cortex in order to build
motor patterns based on the current environment and desires as
well as on past experience (Graybiel, 2008; Figure 1A). Distinct,
largely parallel cortico-basal ganglia-thalamo-cortico loops have
been proposed to control different aspects of behavior (Alexander
et al., 1986) and different stages of behavioral learning (Yin et al.,
2008). There are marked changes in activity across the striatum
as animals undergo the transition from early-stage, goal-directed
motor learning to habitual, goal-independent behaviors (Thorn
et al., 2010). Lesion studies suggest that the ventromedial striatum
drives the early stages of motor learning and that the dorsolat-
eral striatum is more important for the development of habitual
behaviors (Yin et al., 2004; Atallah et al., 2007). Considering its
key function in reward-based learning, it is no surprise that the
striatum is implicated in a wide variety of behaviors. This breadth
of function is strikingly exhibited in the range of clinical disorders
for which abnormal functioning of the striatum has been found,
including not only classical motor disorders: Parkinson’s disease
(PD), Huntington’s disease (HD), and dystonia, but also habit
formation and drug addiction, impulsivity and attention-deﬁcit
hyperactivity disorder (ADHD), compulsivity and obsessive com-
pulsive disorder, emotional control, and depression (for review,
see Graybiel and Mink, 2009).
Incoming cortical activity is modulated in the striatum by neu-
rochemicals that reﬂect mood, motivation, and expectation. The
striatum is heavily enriched in a number of neurochemical recep-
tor systems including those for dopamine, acetylcholine, endo-
cannabinoids, and endogenous opiates (Graybiel, 1990). Striatal
circuits for appropriate behaviors can thus be engaged accord-
ing to the neurochemical receptors that they express. For example,
mediumspiny striatal projectionneurons (MSNs) that are part of a
circuit that promotes movement express the Drd1 (D1) dopamine
receptor, which boosts MSN cell excitability. MSNs that are part
of a circuit that suppresses movement express the Drd2 (D2)
dopamine receptor, which diminishes excitability of this MSN
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FIGURE 1 | Neuroanatomical connections of the basal ganglia. (A)
Schematic diagram of major basal ganglia circuits with highly schematized
indications of component functions. The striatum with its matrix (M) and
striosomal (S) compartments is centered in the diagram. Four major
pathways are emphasized: the direct (1) and indirect (2) pathways, the
hyperdirect pathway (3), and the striosomal pathway (4). Reprinted with
permission fromThe Cognitive Neurosciences, 4th Edition (Graybiel and
Mink, 2009). (B) Model of the direct, indirect, and striosome-speciﬁc
striatal projection pathways from the dorsal striatum. The diagram is
based on a cross-section through the striatum of an adult rat,
immunostained for CalDAG-GEFII. Striosomes are shown in blue, and the
extra-striosomal matrix in orange. Shading of the striatum from medial
(right) to lateral (left) schematically indicates limbic, associative, and
sensorimotor striatal domains. Arrows ﬂowing into the striatum are
colored to represent the relative abundance of inputs from limbic cortical
regions to striosomes and from sensorimotor and associative regions to
the matrix. Arrows exiting the striatum represent GABAergic efferent
connections from the medium spiny projection neurons (MSNs) in the
striosome and matrix compartments to their respective downstream
target nuclei. The nucleus accumbens is shown in gray. GPe, external
segment of the globus pallidus; GPi, internal segment of the globus
pallidus (entopeduncular nucleus, in rodents); SNr, substantia nigra pars
reticulata; SNc, dopamine-containing substantia nigra, pars compacta; AC,
anterior commissure; STN, subthalamic nucleus.
cell-type. Thus, dopamine has a pro-movement effect by simul-
taneously promoting and disinhibiting movement through the
so-called direct and indirect pathways, respectively (Albin et al.,
1989; Delong, 1990).
Balanced regulation of the direct and indirect pathways is
important for motor control, as evidenced by deﬁcits associ-
ated with selective disruption of either the direct pathway (D1-
enriched), or the indirect pathway (D2-enriched). The direct path-
way MSNs target primarily two nuclei of the basal ganglia – the
internal segment of the globus pallidus (GPi), known in rodents
as the entopeduncular nucleus (EP), and the substantia nigra pars
reticulata (SNr; Figure 1B). The SNr and GPi in turn send their
outputs to brainstem nuclei and to components of themotor thal-
amus, which excite cortical areas related to motor control. The
indirect pathway MSNs project to the external pallidal segment
(GPe,often known simply as the globus pallidus in rodents),which
inversely controls these same thalamo-cortical motor circuits.
Support for this model, oversimpliﬁed as it undoubtedly is, has
ﬂourished with the development of genetically engineered mice
and cell-type speciﬁc viral vectors in which the direct and indirect
pathways can be separately characterized and controlled, includ-
ing by optogenetic intervention (Valjent et al., 2009; Kravitz and
Kreitzer, 2011). Such studies have contributed to our understand-
ing of symptoms and therapies in movement disorders, including
PD and HD, in which there is neurodegeneration of basal ganglia
nuclei (Albin et al., 1989, 1995).
Studies of how the striatum controls movement have focused
heavily on dopamine and the direct and indirect pathways. A less
well-studied but equally distinct pair of striatal circuits originates
in striatal compartments that are known as the striosomes (or
patch) and matrix. These compartments can be deﬁned by their
pronounced segregation of numerous neurotransmitter-related
signaling molecules (Graybiel, 1990). The striosomal compart-
ment of the dorsal striatum forms a labyrinthine, interconnected
structure that is embedded in the surrounding striatal matrix
(Pert et al., 1976; Graybiel and Ragsdale, 1978; Herkenham and
Pert, 1981; Gerfen, 1984). Whereas the main afferent connec-
tions of the matrix are related to associative and sensorimotor
regions, striosomes have predominant limbic-related connections
(Jimenez-Castellanos and Graybiel, 1987; Gerfen, 1989; Eblen and
Graybiel, 1995; Kincaid and Wilson, 1996). Both striosomes and
matrix contain MSNs that project to the direct and indirect path-
way target nuclei but, in some documented cases, to separate sub-
regions. Most, but not all, of the local connectivity of these MSNs
is with other neurons within their own compartment or with
interneurons located near the compartment borders (Somogyi
et al., 1981; Gerfen, 1984; Walker et al., 1993; Kincaid andWilson,
1996; Tokuno et al., 2002; Levesque and Parent, 2005; Fujiyama
et al., 2006, 2011). The striosome compartment is thought to con-
tain the only striatal neurons that have direct projections to the
substantia nigra, pars compacta (SNc), which contains dopamine-
producing neurons that project back to the entire dorsal striatum
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(Gerfen, 1984; Jimenez-Castellanos and Graybiel, 1989; Tokuno
et al., 2002; Fujiyama et al., 2011).
The striosome and matrix compartments are typically deﬁned
by their gene expression proﬁles. Upward of 60 genes are reported
to be differentially expressed in the striosomes and matrix
(Table 1). This review is based on the proposition that these dis-
tinct molecular expression patterns are likely to reﬂect specialized
processing by striosome-based circuits of the basal ganglia. As
evidence already suggests that striosomes and matrix have dif-
ferential vulnerability patterns in some basal ganglia-associated
disorders, there is a clear need to understand how these com-
partments inﬂuence behavior in health and disease. Until very
recently, the functions of striosomes and matrix have been sur-
mised primarily on the basis of their activation proﬁles, mainly by
immediate early gene (IEG) induction assays, and on the basis of
their distinct input–output connections. The creation of genetic
tools by which these two compartments can be selectively manip-
ulated will certainly shed light on their function. Here, we review
differences between the striosomes and matrix at the anatomical
and gene expression level and differences between these two com-
partments in a wide variety of diseases associated with abnormal
movement and emotion.
DISTINGUISHING FEATURES OF THE STRIOSOME AND
MATRIX COMPARTMENTS OF THE DORSAL STRIATUM
DEVELOPMENT OF THE STRIOSOME AND MATRIX COMPARTMENTS
A striosome-substantia nigra-striatum circuit is established rela-
tively early in the developing striatum. The striosomal neurons
are born in a discrete time-window, during the time that layer 6
neurons of the neocortex are born (Graybiel and Hickey, 1982), as
though forming an ontogenetic unit. They begin to migrate out
from the lateral ganglionic eminence earlier in development than
most matrix neurons, which are mainly born later in embryoge-
nesis. The developing striosomes correspond to the “dopamine
islands” formed by incoming dopamine-containing nigrostriatal
ﬁbers (Olson et al., 1972; Graybiel, 1984;Moon Edley andHerken-
ham, 1984; Fishell and Van Der Kooy, 1987). Anatomical studies
suggest that the clusters of MSNs in the proto-striosomes begin
to mature just in advance of the dopamine-containing ﬁbers that
demarcate the clusters (Newman-Gage and Graybiel, 1988). The
dopamine-containing ﬁber input to striosomes is nevertheless
required for the expression of some striosomal markers, including
the mu opioid receptor (Van Der Kooy and Fishell, 1992).
The protostriosomal neurons project to developing dopamine-
containing neurons in the ventral mesencephalon and secrete
Reelin (Nishikawa et al., 1999), a protein that is essential for the
lateral migration of dopamine-containing neurons that come to
form the SNc (Nishikawa et al., 2003). The neurotrophic factor,
GDNF, is also enriched in striosomes, and its expression in the
striatum is important for survival of the dopamine-containing
neurons (Lopez-Martin et al., 1999; Oo et al., 2005). As later-born
matrix neurons migrate out into the striatum, they form caudal-
to-rostral and lateral-to-medial gradients of migration, beginning
around E20 in rats (Liu and Graybiel, 1992) and at compara-
ble times in cats (Newman-Gage and Graybiel, 1988). Peri-natally,
cell-type speciﬁc expression of ephrins and their receptors serve to
compartmentalize the MSNs into striosome and matrix compart-
ments (Janis et al., 1999; Passante et al., 2008). Finally, extracellular
matrix proteins and peri-neuronal nets have dynamic compart-
mental distributions that may contribute to the consolidation of
synaptic circuits and the mature appearance of the striatum by
about P20 (Liu and Graybiel, 1992; Lee et al., 2008).
In adulthood, striosomes make up roughly 15% of the volume
in the dorsal striatum (Johnston et al., 1990) of humans,monkeys,
rats, and mice and they are largest in the rostral and medial parts
of the striatum – to be precise, themedial and anterior caudoputa-
men in rodents and the caudate nucleus and anterior putamen in
primates (Graybiel and Ragsdale, 1978). Striosome–matrix com-
partmentalization is largely, but not entirely, observed by the den-
drite and local axon collaterals of striatal neurons.MSNshave axon
collaterals that mainly synapse onto neighboringMSNs within the
same compartment, and the dendritic trees of MSNs tend to be
compartmentally conﬁned (Walker et al., 1993; Kincaid and Wil-
son, 1996; Yung et al., 1996; Fujiyama et al., 2011). It is thought
that differential activation of striosomes andmatrix could bemod-
ulated, in part, by differentially distributed striatal interneurons,
including cholinergic interneurons and somatostatin/nitric oxide
synthase-positive interneurons that tend to be located at compart-
ment borders (Graybiel et al., 1986; Kubota and Kawaguchi, 1993;
Aosaki et al., 1994; Saka et al., 2002; Miura et al., 2007).
A number of transcription factors, including Ctip2 (Arlotta
et al., 2008), RARβ (Liao et al., 2008), and Dlx1/2 (Ander-
son et al., 1997) are required for the differentiation of MSNs.
The compartment-enriched expression of multiple genes has
been found to change not only prenatally, but also during the
period between birth and maturity, as the compartmental pat-
tern matures. Remarkably, despite the limitation of anatomical
marking of post-mortem human brain sections, evidence sug-
gests that the outlines of this developmental pattern are visible
in humans. Striosomes have been identiﬁed in prenatal striatum
by histochemical (acetylcholinesterase) staining methods and a
switch in the compartmental staining with this marker occurs
during the postnatal period (Graybiel and Ragsdale, 1980). There
are also cross-species variations in compartmental gene enrich-
ment. Table 1 summarizes molecules reported to be differentially
expressed in striosomes or extra-striosomal matrix, with a bias
toward differences reported in adult animals.
COMMON AND DISTINCT EFFERENT CONNECTIONS OF THE
STRIOSOME AND MATRIX COMPARTMENTS
Deﬁnitive evidence about the connections of striosomalMSNs has
been difﬁcult to obtain for technical reasons, but a recent study
based on single-neuron labeling now suggests that in adult rats,
striosomal MSNs may be unique among striatal MSNs in pro-
jecting directly to the SNc, which contains dopamine-producing
neurons (Fujiyama et al., 2011). This single-neuron evidence is
in accord with earlier work with classical anterograde and ret-
rograde tracing methods (Gerfen, 1985; Jimenez-Castellanos and
Graybiel, 1989; Tokuno et al., 2002). One such retrograde labeling
experiment indicated that the densocellular zone of the SNc,which
exhibits low levels of acetylcholinesterase (AchE) immunoreactiv-
ity relative to the surrounding region, is preferentially targeted by
striosomes, which are also AchE-poor (Jimenez-Castellanos and
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Table 1 | Molecules with differential expression between the striosome and matrix compartments of the dorsal striatum.
Gene/protein
abbreviation
Full name Species Reference
STRIOSOME-ENRICHED
5HT2a Serotonin receptor type 2a Human; monkey; mouse Lopez-Gimenez et al. (1999, 2001, 2002)
5HT2c Serotonin receptor type 2c Rat Ward and Dorsa (1996)
AADC Aromatic, l-amino acid decarboxylase Early postnatal mouse Kim et al. (2002)
Adora2A Adenosine receptor type 2A Early postnatal rat Schiffmann and Vanderhaeghen (1992)
Bcl-2 B-cell CLL/lymphoma 2 Monkey Bernier and Parent (1998)
C3HC4 Membrane-associated ring ﬁnger 4 Mouse Gensat (Gong et al., 2003)
CalDAG-
GEFII/RasGRP
Calcium/diacylglycerol-regulated guanine
nucleotide exchange factor II
Rat Pierret et al. (2002), Crittenden et al. (2009)
CALB2 Calretinin Mouse Davis and Puhl (2011)
CHRM Cholinergic receptors, muscarinic (ligand
binding assay)
Fetal human; E50 and adult
cat; Ferret; Rat
Nastuk and Graybiel (1985)
Cxcr4 Chemokine (C-X-C motif) receptor 4 P7 mouse Gensat (Gong et al., 2003)
DARPP-32 Dopamine and cAMP-regulated
phosphoprotein 32 kDa
P0 mouse Arlotta et al. (2008)
Drd1 Dopamine receptor D1 Human; monkey; cat; rat;
early postnatal mouse
Besson et al. (1988), Murrin and Zeng (1989),
Kim et al. (2002)
Drd4 Dopamine receptor D4 Monkey; rat; mouse Rivera et al. (2002)
CD73 Ecto-5′-nucleotidase (enzymatic assay) Rat Schoen and Graybiel (1992)
Egr1 Early growth response 1 P7 mouse Gensat (Gong et al., 2003)
EphA7 Ephrin receptor A7 P7 mouse Gensat (Gong et al., 2003)
Fam131 Family with sequence similarity 131,
member B
Mouse Gensat (Gong et al., 2003)
FoxP2 Forkhead box P2 Prenatal monkey; P3-P20 Takahashi et al. (2003, 2008)
Gαolf Olfactory type G-protein, alpha subunit Mouse Sako et al. (2010)
Gad2/Gad65 Glutamate decarboxylase 2 Mouse Gensat (Gong et al., 2003)
GDNF Glial cell line-derived neurotrophic factor Early postnatal rat Lopez-Martin et al. (1999)
GluR1 Glutamate receptor, ionotropic, AMPA 1 P0 mouse Martin et al. (1993a,b), Arlotta et al. (2008)
GRIK Glutamate receptor, ionotropic, kainate
(ligand binding assay)
Human Dure et al. (1992)
HTT Huntingtin protein Rat Kosinski et al. (1997)
IP3R Inositol 1,4,5-triphosphate receptor Monkey Fotuhi et al. (1993)
Kcnip2 Kv channel-interacting protein 2 P0 mouse Arlotta et al., 2008)
KChIP1 Kv4 potassium channel subunit potassium
channel-interacting protein 1
Monkey Mikula et al. (2009)
LSAMP Limbic system-associated membrane protein Cat Chesselet et al. (1991)
MAP2 Microtubule-associated protein 2 P0 mouse Arlotta et al. (2008)
MOR1 Opioid receptor, mu 1 Rat; mouse; P0 mouse Herkenham and Pert (1981), Arlotta et al. (2008)
Nnat Neuronatin Mouse Gensat (Gong et al., 2003)
NPY2R NeuropeptideY receptor Y2 P7 mouse Gensat (Gong et al., 2003)
N-TAF1 TBP-associated RNA polymerase II Rat Sako et al. (2011)
Ntrk3 Neurotrophic tyrosine kinase receptor type 3 Mouse Gensat (Gong et al., 2003)
Nur77/NR4a1 Nuclear hormone receptor Mouse Davis and Puhl (2011), Gensat (Gong et al., 2003)
PBX3 Pre-B-cell leukemia homeobox 3 Prenatal monkey Takahashi et al. (2008)
PCDH OL-Protocadherin P2 mouse Redies et al. (2002)
Pdyn Prodynorphin Mouse Gensat (Gong et al., 2003)
Phactr1 Phosphatase and actin regulator P7 mouse Gensat (Gong et al., 2003)
PIK3R1 Phosphoinositide-3-kinase, regulatory
subunit 1 (alpha)
P7 mouse Gensat (Gong et al., 2003)
PLCgamma Phospholipase C, gamma Primate Fotuhi et al. (1993)
(Continued)
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Table 1 | Continued
Gene/protein
abbreviation
Full name Species Reference
PLCbeta Phospholipase C, beta Primate Fotuhi et al. (1993)
RELN Reelin P3 rat; P0 mouse Nishikawa et al. (1999), Arlotta et al. (2008)
SCG2 Secretogranin II P7 mouse Gensat (Gong et al., 2003)
SpdS Spermidine synthase Rat Krauss et al. (2006)
MATRIX-ENRICHED
5HT2a Serotonin receptor type 2a Rat Ward and Dorsa (1996)
AchE Acetylcholinesterase Monkey; cat; rat Herkenham and Pert (1981), Graybiel (1984),
Graybiel et al. (1986)
CaBP Calcium-binding protein Monkey; rat Gerfen et al. (1985)
CALB1 Calbindin 1, 28 kDa Human; monkey; rat;
embryonic rat; mouse
Martin et al. (1991), Ito et al. (1992),
Liu and Graybiel (1992), Davis and Puhl (2011)
CalDAG-
GEFI/RasGRP2
Calcium/diacylglycerol-regulated guanine
nucleotide exchange factor I
Rat; mouse Kawasaki et al. (1998), Crittenden et al. (2010a)
Cb1 Cannabinoid receptor 1 Human Villares (2007)
CDH8 Cadherin-8 P0–P8 rat Korematsu et al. (1998)
Cdk5-pY15 Cyclin-dependent kinase 5, phosphorylated
at Y15
Mouse Morigaki et al. (2011)
ChAT Choline O-acetyltransferase Human; monkey; cat Graybiel et al. (1986), Hirsch et al. (1989)
Ebf1 Early B-cell factor 1 P0 mouse Liao et al. (2005), Arlotta et al. (2008)
EphA4 Ephrin receptor A4 Rat Martone et al. (1997)
GluR Glutamate receptors, AMPA (ligand binding
assay)
Human Dure et al. (1992)
Htr4 5-hydroxytryptamine (serotonin) receptor 4 Mouse Gensat (Gong et al., 2003)
NADPH
diaphorase
NADPH diaphorase (enzymatic activity assay) Human; cat Sandell et al. (1986), Morton et al. (1993)
Preproenk Enkephalin GFP reporter mice Koshimizu et al. (2008)
SOD2 Superoxide dismutase 2, mitochondrial Human; monkey Zhang et al. (1994), Medina et al. (1996)
SST Somatostatin Rat Gerfen et al. (1985)
TH Tyrosine hydroxylase Human; monkey; early
postnatal cat; early postnatal
mouse
Graybiel (1984), Graybiel et al. (1987)
VGluT2 Vesicular glutamate transporter 2 Rat Fujiyama et al. (2006)
Differential immunoreactivity can result from differential expression in MSNs, striatal interneurons or afferents that preferentially target one compartment. When
developmental stage is not indicated, the ﬁnding was made in adults. P, postnatal day; E, embryonic day.
Graybiel, 1989). In the rat, the striatonigral ﬁbers have been sug-
gested to form symmetric synapses on both the dendrites and cell
bodies of the dopamine-containing neurons (Somogyi et al., 1981;
Gerfen,1984;Tokunoet al.,2002;Fujiyamaet al.,2011).Amonosy-
naptic connection between MSNs and dopamine-producing cells
of the SNc is also consistent with electrophysiological recording
assays in rats (Lee and Tepper, 2009). If conﬁrmed by further
work, the direct striosome-SNc projection would parallel a ven-
tral striatal input to the SNc (Somogyi et al., 1981). The striosomes
and ventral striatum are in a position to exert global control over
dopamine signaling in the dorsal striatum.
Aside from this connection, both striosomes and matrix share
in projecting to the main output nuclei of the basal ganglia, but in
different proportions. These projections are more abundant from
the large matrix compartment (Gerfen and Young, 1988; Jimenez-
Castellanos and Graybiel, 1989; Rajakumar et al., 1993; Tokuno
et al., 2002; Levesque and Parent, 2005; Fujiyama et al., 2011).
Efferents from MSNs in the matrix have consistently been found
not to project to the SNc but, rather, to project to the GPe,GPi, and
SNr (Gerfen, 1984; Kawaguchi et al., 1990; Gimenez-Amaya and
Graybiel, 1991; Levesque and Parent, 2005; Chuhma et al., 2011;
Fujiyama et al., 2011). Likewise, a juxtacellular labeling experi-
ment identiﬁed sixMSNs, all located within the same striosome in
the striatum of a squirrel monkey, that had projections to the GPi,
GPe, and non-dopaminergic SNr, rather than to the dopamine-
containing SNc (Levesque and Parent, 2005). Striosomal MSNs
targeting the GPi, GPe, and SNr have also been reported in the rat.
Striosomal MSNs that target the GPi/EP are reported to innervate
speciﬁcally the regions of the GPi that in turn project to the lateral
habenula, whereas the matrix MSNs targeting GPi/EP project to
regions that are interconnected to motor regions of the thalamus
(Rajakumar et al., 1993). This pathway to the habenula is notable,
because the lateral habenula, itself interconnectedwith the prelim-
bic cortex, can inhibit dopamine cell ﬁring in the SNc (Herkenham
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andNauta, 1979; Christoph et al., 1986; Ji and Shepard, 2007;Mat-
sumoto and Hikosaka, 2007; Bromberg-Martin et al., 2010). Thus,
the striosomes appear to represent a unique dopamine- and limbic
system-related circuit that is situated to inﬂuence the associative
and sensorimotor regions of the striatum.
Based on these ﬁndings, a three-compartment model of stri-
atal efferent connectivity has been proposed, including: (1) the
direct pathway targeting the SNr with collaterals in the GPi/EP
and GPe, (2) the indirect pathway targeting only the GPe, and (3)
the striosome-speciﬁc pathway targeting the SNc, with collaterals
in the GPi/EP and GPe (Figure 1B; Graybiel et al., 2000; Fujiyama
et al., 2011). The apparently unique projection of striosomes to the
SNc, if conﬁrmed,would place striosomes in a functionally pivotal
position to inﬂuence the dopamine system of the midbrain.
RELATIONSHIP BETWEEN THE DIRECT–INDIRECT PATHWAY DIVISIONS
AND STRIOSOME–MATRIX COMPARTMENTS
MSNs can be classiﬁed according towhether they give rise to either
the direct or indirect pathways, and they can also be classiﬁed
according to whether they are in striosomes or in the extra-
striosomal matrix. These are two distinct classiﬁcatory schemes.
Most of the neurons of direct and indirect pathways lie in the
matrix, which makes up approximately 80% of the volume of
the striatum. There is evidence that some neurons in striosomes
project to direct pathway targets, and others (fewer in num-
ber) project to indirect pathway target nuclei. Single-ﬁber tracing
methods have allowed deﬁnitive identiﬁcation of the collaterals of
efferent axons of neurons identiﬁed as belonging to either strio-
somes or matrix. Fujiyama et al. (2011) labeled 11 striosomal
neurons that were distributed across the striatum and in differ-
ent rats, and found that 8 projected to the SNc, with collaterals in
one or more of the direct pathway targets (SNr, GPi/EP, and GPe)
and 3 exhibited an indirect pathway projection pattern, solely to
the GPe. Similarly, in the monkey labeling experiment by Parent
and colleagues, all six of the labeled striosomal neurons projected
to the direct pathway nuclei (Levesque and Parent, 2005). Thus, at
least some striosomes have an overabundance of neurons that tar-
get GPi/EP and SNr, but they may target speciﬁc regions of these
nuclei, relative to matrix MSNs. In the matrix, as a whole, the
MSNs are equally divided between the direct and indirect pathway
projection types. MSNs that target the SNc appear to be restricted
to the striosomes and are not found in the matrix.
Direct and indirect pathway MSNs are often identiﬁed by
their expression of peptides in addition to their expression of
dopamine receptors. Direct pathway D1-positive MSNs express
substance P and prodynorphin, whereas the indirect pathway
D2-positiveMSNs express proenkephalin/enkephalin (Gerfen and
Young, 1988). In adult rats, an estimated 5% of MSNs in the
dorsal striatum express both D1/substance P and D2/enkephalin,
whereas co-expression in the ventral striatum may be slightly
higher (Surmeier et al., 1996;Wang et al., 2006a; Bertran-Gonzalez
et al., 2008; Perreault et al., 2010). D1/D2 heteromers have been
discovered and are thought to signal through phospholipase C,
a calcium-dependent signaling cascade, rather than through the
canonical adenylyl cyclase, cAMP-dependent dopamine receptor
signaling cascade (Lee et al., 2004; Perreault et al., 2010). Neu-
rons that co-express substance P and enkephalin have been found
in both striosomes and matrix, but may represent a greater pro-
portion of the MSNs in the striosomal compartment than in
the matrix (Besson et al., 1990; Wang et al., 2007). Furthermore,
co-expression of substance P and enkephalin was abundant in ter-
minals in the SNc, but not in the GPe, GPi, or SNr (Wang et al.,
2006a). Thus, it is possible that some of the unique subset of
striosomal neurons that target the SNc co-express D1 and D2.
This would stand in contrast to the direct pathway neurons of
the matrix, which express primarily D1. However, the expression
proﬁles of the striosome-speciﬁc pathway MSNs, which target the
SNc, have not yet been thoroughly analyzed. Such analysis should
take into account that the expression levels of the proteins that are
typically used to deﬁne the pathways and compartments, includ-
ing prodynorphin, mu opioid receptor, and dopamine receptors,
can change with experience (Moratalla et al., 1996; Cenci et al.,
1998; Adams et al., 2003; Jabourian et al., 2005; Perreault et al.,
2010).
In summary,data support amodel inwhichMSNs projecting to
the SNc are conﬁned to striosomes (striosome-speciﬁc pathway),
whereas MSNs contributing to the direct and indirect pathway
are present mainly in the matrix compartment but also in strio-
somes. The direct and indirect pathway target nuclei (GPi, SNr,
and GPe/EP) receive more inputs from MSNs in the matrix than
those in striosomes, because the matrix compartment is much
larger than the striosomal compartment. The balance of signaling
between the direct and indirect pathways is strongly inﬂuenced
by dopamine and, therefore, striosomal MSNs are in a position
to control this balance through their projection to the dopamine-
containing neurons of the SNc. Cholinergic interneurons, which
are often located at the border between striosomes and matrix,
can also control dopamine release (Threlfell and Cragg, 2011) and
the balance of direct vs. indirect pathway activation (Ding et al.,
2011).
Amemori et al. (2011) propose a model whereby striosomes
and indirect pathway MSNs select modules of previously learned
behaviors that are appropriate for the given environmental con-
text. In this model, the direct pathway selects speciﬁc actions
within each striatalmodule,whereas the indirect pathway serves to
select amongmodules. Based on contextual prediction errors orig-
inating in the limbic system, striosomes provide “responsibility
signals” that regulate the activity of adjacent matrix MSNs within
their respective modules. This modular regulation is ampliﬁed
through the indirect pathway by virtue of funneling of repre-
sentations, which serves to select modules (rather than speciﬁc
actions) based on contextual information. This model is sup-
ported by computational modeling experiments and would sup-
port context-dependent learning and faster behavioral adaptation
in a ﬂuctuating environment.
CEREBRAL CORTEX AFFERENTS TO STRIOSOME AND MATRIX
COMPARTMENTS
Although amajority of neocortical areasmay project to both strio-
somes andmatrix, there aremajor differences in the strength of the
projections to the two compartments. In keeping with the concept
that ontogeny recapitulates phylogeny, striosomal MSNs not only
begin differentiating before matrix MSNs, but also are innervated
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by neurons in more evolutionarily conserved regions of the cere-
bral cortex, especially the limbic medial and lateral margins of
the cortical plate (Ragsdale and Graybiel, 1988; Gerfen, 1989). The
orbitofrontal, anterior cingulate, and insular cortices preferentially
innervate striosomes, whereas projections from the somatosen-
sory, motor, and association cortices terminate mainly in the
matrix (Ragsdale and Graybiel, 1990; Flaherty and Graybiel, 1994;
Eblen andGraybiel, 1995; Kincaid andWilson, 1996; Levesque and
Parent, 1998). The amygdala, hippocampus, and nucleus accum-
bens (part of the ventral striatum) are interconnected with the
orbitofrontal, anterior cingulate, and insular cortices, supporting
the idea that the striosomes are part of a limbic circuit embed-
ded in the sensorimotor and associative striatum (Graybiel, 2008).
Indeed, in the cat, part of the amygdala itself also projects to part
of the striosomal system (Ragsdale and Graybiel, 1988).
The strong innervation of medial striosomes by limbic neocor-
tical regions that have reduced superﬁcial layers is consistent with
the fact that striosomalMSNs receive preferential inputs fromdeep
cortical layer Vb (Gerfen, 1989; Eblen and Graybiel, 1995; Kincaid
andWilson, 1996; Levesque and Parent, 1998).MSNs in thematrix
receive input from ontogenically younger, and putatively evolu-
tionarily younger, cortical layers (III–Va). This is consistent with
the ﬁnding that the somatosensory cortex,which is part of the neo-
cortex that has a well-deﬁned upper layerVa, projects to thematrix
and not to the striosomes (Wilson, 1987; Gerfen, 1989). Neverthe-
less, the correlation between evolutionary age and compartment-
speciﬁc targeting of corticostriatal neurons is speculative and does
not fully represent the types of compartmentalized targeting that
have been observed. For example, labeling of efferents from indi-
vidual cortical regions was found to preferentially ﬁll striosomes
dorsally but to avoid striosomes ventrally, within their striatal tar-
get zones (Ragsdale and Graybiel, 1990). The striatal target zones
themselves progressed dorso-ventrally according to the neighbor-
ing cortical regions from which they arose and thus, neighboring
striosome–matrix compartments received input fromneighboring
cortical regions.
Corticostriatal projection neurons send efferents to other
brain regions, including the brainstem, thalamus, claustrum, and
contralateral cortex (Wilson, 1987; Kincaid and Wilson, 1996;
Levesque et al., 1996). Upper layer V is enriched in intra-
telencephalic-projecting (IT-type) neurons that can bifurcate to
both hemispheres and synapse preferentially onto D1-positive
MSNs. By contrast, deep layer V is enriched in pyramidal tract-
projecting (PT-type) neurons that send collaterals preferentially to
D2-positive MSNs in the ipsilateral striatum (Reiner et al., 2003).
Axon terminals from PT-type cortical neurons were found to be
larger andmoreoften contacted aperforatedpost-synaptic density,
compared to the IT-type corticostriatal terminals that contacted
direct pathway MSNs (Reiner et al., 2010). This is consistent with
the preferential activation of IEGs in enkephalin-containing neu-
rons found in response to activation of the motor cortex (Berretta
et al., 1997; Parthasarathy and Graybiel, 1997). Based on evidence
that afferents to striosomes arise preferentially from deep layers
of limbic cortex, one might expect striosomes to receive prefer-
ential PT-type inputs. However, the properties of corticostriatal
synapses, such as terminal area and post-synaptic density length,
were found to be similarly distributed between striosomes and
matrix (Fujiyama et al., 2006) and both IT-type and PT-type
projections have been detected in striosomes (Donoghue and
Herkenham, 1986; Levesque and Parent, 1998; Wang and Pickel,
1998). These ﬁndings, together with the evidence that striosomes
and matrix both have D1- and D2-dopamine receptor-expressing
MSNs, even if not in equal proportion, indicate that each com-
partment receives input from both IT-type and PT-type cortical
neurons. Reiner et al. (2010) point out that BAC mice express-
ing EGFP in either the PT neurons or the IT neurons will help
to resolve this issue of whether there is preferential compartment
targeting of one projection type.
In summary, each striatal compartment receives preferential
inputs fromdifferent cortical regions and individual corticostriatal
axons tend to innervate MSNs that are conﬁned to a single com-
partment (Kincaid and Wilson, 1996). Nevertheless, subregions
of the striatum that encompass both striosomes and neighbor-
ing clusters of cells in the matrix (matrisomes) are innervated by
related cortical regions (Ragsdale and Graybiel, 1990; Flaherty and
Graybiel, 1995; Kincaid and Wilson, 1996). Thus, MSNs in strio-
somes and matrisomes are thought to process related information
and to communicate selectively with surrounding regions, likely
via interneurons that have dendrites that cross compartmental
borders. Such striatal interneurons include NOS/somatostatin-
positive interneurons and parvalbumin-positive interneurons,
which receive strong input from the cerebral cortex, and cholin-
ergic interneurons, which receive strong input from the thalamus
(Graybiel et al., 1986; Sandell et al., 1986; Lapper and Bolam, 1992;
Lapper et al., 1992; Kubota and Kawaguchi, 1993; Bennett and
Bolam, 1994; Aosaki et al., 1995; Kawaguchi, 1997; Saka et al.,
2002; Miura et al., 2008).
THALAMIC AND NIGRAL AFFERENTS TO STRIOSOME AND MATRIX
COMPARTMENTS
Thalamic and cortical neurons make excitatory, asymmetric
synaptic connections onto MSNs in similar proportions (Doig
et al., 2010). These inputs can be distinguished by immunostain-
ing for the vesicular glutamate transporters VGluT1 (present in
cortical terminals and also in less abundant amygdaloid termi-
nals) and VGluT2 (present in thalamic terminals), according to
evidence from numerous laboratories (Fremeau et al., 2001; Lacey
et al., 2005; Raju et al., 2006).With thesemarkers, it was found that
inputs from the thalamus terminate on both dendritic spines and
dendritic shafts of striatal neurons (Lacey et al., 2005; Raju et al.,
2006), but the inputs to shafts are largely conﬁned to the matrix
(Fujiyama et al., 2006;Raju et al., 2006). This compartmental selec-
tivity is likely due to the fact that inputs from the parafascicular
nucleus, one of the intralaminar nuclei of the thalamus, terminate
onto the shafts of cholinergic interneurons (Lapper and Bolam,
1992), which are abundant in the striatal matrix. The parafascic-
ular inputs also contact spines and shafts of MSNs (Lacey et al.,
2007). The intralaminar thalamic nuclei are highly interconnected
with sensorimotor cortical regions and preferentially target the
matrix (Herkenham and Pert, 1981; Ragsdale and Graybiel, 1991;
Sadikot et al., 1992). By contrast, the midline paraventricular and
rhomboid nuclei of the thalamus, which have strong connections
with the nucleus accumbens and the amygdala,have been shown in
the cat to target striosomes preferentially (Ragsdale and Graybiel,
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1991). This pattern is consistent with striosomes participating in
cortico-striato-thalamic circuits with limbic connections and the
extra-striosomal matrix participating in cortico-striato-thalamic
circuits with sensorimotor connections.
Striosomes and matrix receive dopamine-containing inputs
preferentially from distinct groups of neurons in the SNc. The dis-
tinct localization of the striosome vs.matrix targeting nigrostriatal
neurons has been better documented in rats than in primates (Joel
andWeiner, 2000), but differences have been documented in mul-
tiple species. The striosomal MSNs are innervated by a group of
densely packed dopamine-containing neurons in the ventral tier
of the SNc (the A9 cell group) and groups of clustered dopamine-
containing neurons that are intermingled with neurons of the
SNr (densocellular zone; Gerfen et al., 1987; Jimenez-Castellanos
and Graybiel, 1987; Langer and Graybiel, 1989; Prensa and Par-
ent, 2001). These results suggested that there may be reciprocal
connections between some of the striosomal system, at least of
the so-called subcallosal streak in the lateral striatum, and the
densocellular zone of the SNc (Jimenez-Castellanos and Graybiel,
1989; Prensa and Parent, 2001). Matrix neurons are preferentially
innervated by dopaminergic neurons in the dorsal tier of the SNc,
the retrorubral area (A8 cell group) and the ventral tegmental area
(VTA; A10 cell group; Gerfen et al., 1987; Jimenez-Castellanos
and Graybiel, 1987; Prensa and Parent, 2001). Nevertheless, single
dopamine-containing ﬁbers can innervate both striosomes and
matrix (Matsuda et al., 2009) and, for example, ventral tier SNc
neurons are reported to innervate the matrix surrounding a target
striosome (Prensa and Parent, 2001). The dopamine-containing
axons innervating striosomes are reported to be thicker and to
have more varicosities than those innervating the matrix, even
when the axons are simply different branches from the same inner-
vating neuron (Gerfen et al., 1987; Prensa and Parent, 2001). The
ultrastructure of the dopamine-containing afferents is equivalent
between compartments, however, and situated so as to modulate
both cortical and thalamic excitatory inputs toMSNs (Hanley and
Bolam, 1997;Moss and Bolam, 2008). In addition to this compart-
mental organization of the nigrostriatal system is the well-known
gradient of dopamine-containing inputs whereby the medial VTA
projects to the ventral striatum and the SNc, locatedmore laterally,
projects to the dorsal striatum.
STRIOSOMES, SIGNALING, AND DISEASE
MSNs in the striosomes and matrix exhibit remarkably simi-
lar morphology and baseline electrophysiological proﬁles despite
their divergent expression of numerous signaling molecules
(Kawaguchi et al., 1989; Graybiel, 1990; Trytek et al., 1996; Miura
et al., 2007). However, drug treatments that engage signaling cas-
cades linked to dopamine, acetylcholine, and opioid receptors
evoke strikingly different patterns of IEG induction and electro-
physiologically recorded activity in the two compartments (Gray-
biel et al., 1990b; Krebs et al., 1991; Moratalla et al., 1996; Canales
and Graybiel, 2000; Adams et al., 2003; Saka et al., 2004; Miura
et al., 2007).Disruptionor activationof these sameneurotransmit-
ter signaling cascades can lead to neurologic and neuropsychiatric
disorders. Hence, the compartmentalized patterning of activity is
likely to delineate important distinctions in the operation of the
basal ganglia.
The best documented differences in activation of striosomes
and matrix are for models of drug addiction and models of l-
DOPA-induced dyskinesia (LIDs), two hyper-kinetic disorders in
which there is hyper-responsivity of dopamine receptor signaling.
In clinical studies, differences in neurodegeneration between strio-
some and matrix compartments have been reported for HD and
dystonia, two additional disorders characterized by hyperactiva-
tion of the motor system. Differential degeneration has also been
reported in a few cases of multiple system atrophy with predom-
inantly parkinsonian features (MSA-P) and in animal models of
PD, diseases characterized by hypo-kinesia. All of these disorders
can be accompanied by mood disturbances. Differential degener-
ation of either the striosomes or the surrounding matrix would be
expected to result in an imbalance in the numerous neurotrans-
mitter signaling cascades that are differentially expressed between
the two compartments.
It is notable that drug treatments and disease states can also
induce differential activation of D1- vs. D2-expressing MSNs.
We have reviewed some of these ﬁndings here for comparative
purposes, but how these observations relate to such compart-
mentalized activation is still unclear. It is worth keeping in mind
evidence that striosomes contain a greater abundance of MSNs
that project to the direct pathway nuclei than MSNs project-
ing to indirect pathway nuclei. However, preferential activation
of D1-expressing MSNs cannot always account for predominant
striosomal activation because, in some cases, there is wide-spread
suppression of the matrix compartment, which does not have an
overabundance of D2-expressing MSNs. Furthermore, the iden-
tiﬁcation of SNc-targeting MSNs in the striosomes suggests that
some of the striosomal activation is related to this special pathway.
Here, we focus on prominent neuro-molecular aspects of
each of these diseases, with an emphasis on extracellular signal-
regulated kinases 1 and 2 (ERK1/2) and protein kinase A
(PKA) signaling cascades (Figure 2), and we relate these to the
striosome/matrix imbalances that have been reported (Table 2;
Figure 3).
HUNTINGTON’S DISEASE
Huntington’s disease is a fatal neurodegenerative disease caused by
an expanded CAG repeat in the IT15 gene for Huntingtin protein
(Htt; The Huntington’s Disease Collaborative Research Group,
1993). The CAG expansion encodes a polyglutamine tract that
contributes to aggregation of the mutant Htt. HD is typiﬁed by
the death of striatal MSNs and neocortical neurons and by symp-
tomsof emotional disturbances anduncontrollable, choreicmotor
movements (Bates et al., 2002). HD hyper-kinesia may be linked
in part to the preferential degeneration of D2 dopamine receptor-
expressing MSNs of the indirect pathway, which normally inhibit
movement (Reiner et al., 1988; Delong, 1990; Glass et al., 2000).
Experiments regarding selective vulnerability of either striosome
or matrix compartments have yielded variable results, however
(Table 2).
Early reports indicated that tissue from individuals with early-
stage HD have more severe loss of neurons and immunomarkers
in the striosomes than in thematrix,whereas tissue from late-stage
cases have equivalent neurodegeneration between compartments
(Morton et al., 1993; Hedreen and Folstein, 1995). In mouse
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FIGURE 2 | Simplified diagram of the protein kinase A (PKA) and
extracellular signal-regulated kinase/mitogen-activated protein kinase
(ERK1/2; MAPK) signaling cascades. Both PKA and ERK cascades control
neuronal activity and immediate early gene (IEG) expression in medium
spiny projection neurons of the striatum. D1 dopamine receptors promote
the PKA cascade by activating adenylyl cyclase (AC) whereas D2 dopamine
receptors inhibit AC. D1/D2 heterodimers are positively coupled to
phospholipase C (PLC). The calcium- and diacylglycerol-regulated guanine
nucleotide exchange factors (CalDAG-GEFs), which regulate the ERK1/2
cascade, are differentially expressed in the striosome and matrix
compartments. Imbalances in striosome vs. matrix (IEG) transcription are
implicated in L-DOPA-induced dyskinesias and drug addiction.
models, in which death of MSNs is minimal but neurite pathol-
ogy is evident, there is more Htt aggregate burden and prefer-
ential volume loss in striosomes, relative to matrix (Menalled
et al., 2002; Lawhorn et al., 2008). These patterns are not uni-
versal across individuals or models, and other clinical studies even
found preferential loss of matrix markers (Ferrante et al., 1987;
Seto-Ohshima et al., 1988). Some clarity to this controversy was
provided by a study of 35 HD cases correlating symptomatol-
ogy and compartmental-speciﬁc cell loss analyzed in post-mortem
specimens (Tippett et al., 2007). In this study, reduced cell density
in striosomes is more frequently observed in striatal sections from
the brains of individuals who had presented early on with mood,
rather than motor, symptoms. The emotional symptoms in the
HD cases included depression, anxiety, and compulsively repeti-
tive behaviors. Furthermore, in a follow-up study, it was shown
that cell loss in the anterior cingulate cortex is more severe in
post-mortem tissue samples from the individuals that presented
with primarily emotional symptoms (Thu et al., 2010). Thus, neu-
rodegeneration of components of the striosome limbic loop is
associated with the emotional symptoms that characterize HD.
Considering that post-mortem analysis is typically restricted to
late-stage HD when nearly the entire brain is affected, longitudi-
nal imaging studies, including of pre-symptomatic individuals, are
providing more insight into the correlations between the complex
symptomatology and neuronal degeneration patterns that typify
HD (Rosas et al., 2008; Politis et al., 2011).
Despite the wide-spread expression of the mutant isoform of
Htt in HD, there is disproportionate cell death of striatal MSNs
and cortical pyramidal neurons, relative to loss of local interneu-
rons or to neuronal loss in other brain regions. HD leads to a
large array of cellular changes, including oxidative stress responses,
transcriptional dysregulation, and excitotoxicity. Excitotoxicity is
thought to be evoked, at least in part, by an impaired capacity to
buffer the calcium rise that follows the stimulation of glutamate
and dopamine receptors (Beal, 1998; Bezprozvanny and Hayden,
2004; Tang et al., 2007). Accordingly, disruption of either the
cortical (glutamatergic) or nigral (dopamine-containing) affer-
ents to the striatum is protective in the R6/2 mouse model of
HD (Stack et al., 2007). Neocortical stimulation, D1 dopamine
receptor activation and D2 receptor antagonism can all activate
striatal ERK1/2, which exhibits altered activation patterns in HD
models (Lievens et al., 2002; Roze et al., 2008). ERK1/2 signaling
leads to phosphorylation and activation of the transcription fac-
tors ELK1 and CREB (Figure 2) and, thereby, could contribute
to, or compensate for, the massive transcriptional dysregulation
that occurs in HD (Cha, 2007). Other relevant changes in tran-
scription factors are not discussed here, but even wildtype Htt, as
well as mutant Htt, can directly control transcription (Benn et al.,
2008).
In view of evidence that there are striosome-predominant and
matrix-predominant patterns of cell loss in individual cases of
HD, it is of special interest that two striatum-enriched molecules
that signal through ERK1/2, CalDAG-GEFI, and CalDAG-GEFII
(Figure 2), have strongly compartmentalized patterns of expres-
sion. CalDAG-GEFII (aka RasGRP) is expressed especially in strio-
somes, and CalDAG-GEFI is expressed preferentially in the matrix
compartment. The CalDAG-GEFs are severely down-regulated in
the R6/2 mouse model of HD and in post-mortem striatal tissue
from individuals with HD (Crittenden et al., 2010a,b). This down-
regulation is not a function of the preferential loss of D2-positive
neurons in HD, considering that CalDAG-GEFI and CalDAG-
GEFII are expressed in both prodynorphin and preproenkephalin-
positive striatal neurons (Toki et al., 2001). The CalDAG-GEFs
contain calcium and diacylglycerol binding domains and signal
to the ERK1/2 phosphorylation cascade (Kawasaki et al., 1998)
following the activation of cell surface receptors (Dower et al.,
2000; Guo et al., 2001; Crittenden et al., 2004). For CalDAG-
GEFI, it is known from work in a cortical slice model of HD
that knockdown of CalDAG-GEFI expression blocks at least some
of the deleterious effects of over-expressing a mutant fragment
of the Htt protein (Crittenden et al., 2010a). Thus, the down-
regulation of CalDAG-GEFI that is observed in HD may be
compensatory. The consequences of CalDAG-GEFII dysregulation
in HD models still need to be evaluated. Interestingly, in con-
trast to CalDAG-GEFI, another matrix-enriched calcium-binding
protein, calbindin-D28K, is up-regulated in HD and HD animal
models, and this change has been suggested to be protective against
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Table 2 | Diseases and disease models with disparate striosome vs. matrix properties.
Disorder/model Species Change observed Reference
Huntington’s disease Human Preferential loss of striosomal volume at early stage,
more equivalent at later stages of disease.
Morton et al. (1993)
Huntington’s disease Human Preferential loss of MSNs in striosomes in early
stage of disease.
Hedreen and Folstein (1995)
Huntington’s disease Human Preferential loss of neuronal markers in striosomes
of individuals with predominant mood disorder.
Tippett et al. (2007)
Huntington’s disease Human Preferential volume or cell loss in matrix. Ferrante et al. (1987), Seto-Ohshima et al. (1988)
Huntington’s
disease/excitotoxic insult
Rat Preferential survival of MSNs expressing matrix
immunomarker.
Figueredo-Cardenas et al. (1998)
Huntington’s disease/94Q
expanded repeat knock-in
Mouse Increased aggregate formation in striosomal MSNs. Menalled et al. (2002)
Huntington’s disease/YAC128,
full-length human huntingtin
with 128Q
Mouse Preferential volume loss in striosomes with cell loss
in both compartments.
Lawhorn et al. (2008)
Parkinson’s disease/idiopathic Human Preferential loss of cells in nigrosomes. Damier et al. (1999b)
Parkinson’s disease/MPTP Monkey Preferential loss of cells in nigrosomes and
dopamine terminals in striosomes.
Iravani et al. (2005)
Parkinson’s disease/MPTP Monkey Preferential loss of Nur77 expression in striosomes. Mahmoudi et al. (2009)
Parkinson’s disease/MPTP Monkey Preferential loss of dopamine terminals in matrix. Moratalla et al. (1992)
Parkinson’s disease/MPTP Monkey Preferential preservation of 5-HT1A receptor
immunostaining in striosomes.
Frechilla et al. (2001)
Parkinson’s disease/MPTP Dog Preferential loss of dopamine terminals in matrix. Turner et al. (1988)
Dopamine deﬁciency/weaver
mutation
Mouse Preferential loss of dopamine terminals in
striosomes.
Graybiel et al. (1990c)
Parkinson’s disease with
l-DOPA-induced dyskinesia
Human Up-regulation of prodynorphin in striosomes. Henry et al. (2003)
l-DOPA-induced dyskinesia Monkey Up-regulation of prodynorphin in striosomes Henry et al. (2003)
l-DOPA-induced dyskinesia Monkey Up-regulation of Nur77 in rostral striosomes. Mahmoudi et al. (2009)
Multiple System Atrophy Human Preferential loss of MSNs in the matrix compartment
in mid-phase of disease.
Goto andHirano (1990), Ito et al. (1992), Sato et al.
(2007)
Dystonia DYT3 Human Preferential loss of MSNs in the striosome
compartment in dystonic phase of disease.
Goto et al. (2005)
Dopamine-responsive
dystonia/Pts mutation
Mouse Preferential loss of tyrosine hydroxylase in
striosomal compartment.
Sato et al. (2008)
Drug addiction/cocaine Human Increased dynorphin in striosomes of caudate
nucleus.
Hurd and Herkenham (1993)
Drug addiction/cocaine Monkey Increased striosome to matrix ratio of IEG induction. Hurd and Herkenham (1993), Saka et al. (2004)
Drug addiction/psychomotor
stimulants
Rat Increased striosome to matrix ratio of IEG induction. Graybiel et al. (1990b), Moratalla et al. (1996),
Canales and Graybiel (2000)
Drug
addiction/methamphetamine
Rat Increased preprodynorphin expression in striosomes
of rostral striatum.
Graybiel et al. (1990b), Moratalla et al. (1996),
Canales and Graybiel (2000), Adams et al.
(2003)
Drug addiction/MDMA Mouse Preferential loss of dopamine terminals in
striosomes.
Adams et al. (2003), Granado et al. (2008)
Drug
addiction/methamphetamine
Mouse Preferential loss of dopamine terminals in
striosomes.
Granado et al. (2008), Granado et al. (2010)
Neonatal hypoxic ischemia Rat Preferential survival of striatal neurons that express
matrix marker.
Burke and Baimbridge (1993)
Suicide Human Increased dynorphin in striosomes of caudate
nucleus.
Hurd et al. (1997)
Schizophrenia Human Increased asymmetrical axospinous synapses in
striosomes of putamen and in matrix of caudate
nucleus.
Roberts et al. (2005)
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FIGURE 3 | Models of striosome–matrix signaling imbalances in
disease. Schematic diagram illustrating relative activity or cell density
(dense stipple for high activity, sparse stipple for low activity) found in
studies of human brain and brains of animal models. For the diseases or
disease models listed, observations were made of either a relative
imbalance in MSN cell density, immunomarker expression or IEG
induction favoring the striosomes (A) or matrix (B), relative to the
opposite compartment. The diagram is based on a cross-section through
the striatum of an adult human, immunostained for choline
acetyltransferase. Medial is to the right. CN, caudate nucleus; P,
putamen; IC, internal capsule; LID, L-DOPA-induced dyskinesia; MSA-P,
multiple system atrophy with parkinsonian features; HD, Huntington’s
disease; DYT3, X-linked dystonia-parkinsonism; DRD,
dopamine-responsive dystonia (DYT5).
calcium-induced excitotoxicity (Huang et al., 1995; Sun et al.,
2005). Most striatum-enriched genes are down-regulated in HD
however (Desplats et al., 2006), which may be a compensatory
response to the differential vulnerability of the MSN cell-type to
mutant Htt expression.
PARKINSON’S DISEASE AND PARKINSONISM
Parkinsonian disorders are characterized by difﬁculty initiating
movements, bradykinesia,muscle rigidity, and postural instability.
Idiopathic PD is an age-related neurodegenerative disease sec-
ond only to Alzheimer’s disease in prevalence. PD is typiﬁed by
degeneration of dopamine-containing neurons in the SNc, which
results in the loss of the dopamine-containing innervation of
the striatum, usually with a progression of loss from posterior
regions (putamen) that are important for the execution of volun-
tary movements toward anterior regions (caudate nucleus) that
are more associative and limbic in function (Kish et al., 1988). PD
is now thought to arise from an interaction between the environ-
ment and genetic susceptibility. Exposure tomitochondrial toxins,
such as the pesticide rotenone or MPTP-tainted drugs of abuse,
are well-documented risk factors (Shulman et al., 2011). A num-
ber of genetic mutations can lead to PD, including mutations in
SNCA, which encodes alpha-synuclein and for which there is a
gene dosage effect that correlates with the severity of disease (Sin-
gleton et al., 2003; Chartier-Harlin et al., 2004; Farrer et al., 2004).
The pathologic SNc hallmark of PD has long been identiﬁed as the
large cytoplasmic inclusions known as Lewy bodies, and these are
highly enriched in alpha-synuclein protein.
Different groups of dopaminergic neurons within the SNc
appear to have different vulnerability to cell death inPD. For exam-
ple, the loss of neuronswithin the densely packed cell groups called
nigrosomes correlates with disease duration, whereas dopamine-
containing neurons in surrounding parts of the SNc are less vul-
nerable (Damier et al., 1999b). The“nigrosomes”of the substantia
nigra share with the striosomes of the dorsal striatum the char-
acteristic of being weakly immunoreactive for calbindin-D28k,
relative to other nigral regions (Damier et al., 1999a). A study
assessing neuronal loss in a single section through the caudal
SNc of 20 PD cases and 36 control cases found preferential loss
of pigmented cells in the ventro-lateral SNc in PD, relative to
age-related loss of more dorsally located pigmented neurons in
controls (Fearnley and Lees, 1991). A second study also reported
increased vulnerability of neurons located in the ventro-lateral
SNc that are calbindin-D28k-negative (Yamada et al., 1990), but
this pattern is not uniform across studies and is likely dependent
on the individual and how the SNc subregions are deﬁned (Hirsch
et al., 1988; Gibb, 1992). Direct measurements of differential stri-
atal loss of dopamine-containing terminals in striosomesormatrix
have not yet been possible because in nearly all PD cases that come
to autopsy, the depletion of dopamine is so extensive that markers
of the nigrostriatal innervation yield little or no signal.
Differential loss of dopamine terminals in the strio-
somes, relative to matrix, is observed in a mouse model of
dopamine deﬁciency, weaver, which carries a mutation in the
GIRK2/Kir3.2/KCNJ6 gene that encodes a G-protein-activated
inwardly rectifying potassium channel (Graybiel et al., 1990c).
However, systemic deﬁcits in weaver mice, including in the cere-
bellum, preclude simple interpretation of motor effects from their
striosomal dopamine deﬁciency. Overall, results from neurotoxin-
induced dopamine depletion in animal models of PD have
been mixed, with some reporting increased dopamine termi-
nal loss from striosomes and others increased loss from matrix
(Table 2). This inconsistency may be related to the fact that the
site of intracerebral neurotoxin injection inﬂuences the pattern of
compartment-selective terminal loss (Zahm, 1991). These stud-
ies are further confounded by the fact that the immunomarker
typically used to label dopamine terminals, anti-tyrosine hydrox-
ylase (TH) immunoserum, shows higher immunoreactivity in the
matrix than in striosomes of normative animals in some species.
This differential anti-TH immunoreactivity is observed promi-
nently in primates, including in humans, and weakly in rodents
(Graybiel et al., 1987). This mosaic pattern of TH immunostain-
ing was found to be preserved in several post-mortem PD cases,
but could only be assessed in the most ventral parts of the caudate
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nucleus and putamen that were not fully depleted of this marker
(Graybiel et al., 1990a). Immunostains for thematrix or striosome
MSNs themselves also show grossly normal mosaic staining pat-
terns in striatal sections from individuals with idiopathic PD or
in cases of parkinsonism-dementia complex of Guam (Ito et al.,
1992, 1993).
In a rare form of parkinsonism, MSA-P, differential matrix vs.
striosome MSN degeneration has been reported. In MSA-P, there
is degeneration of multiple neuronal types, including MSNs and
nigral neurons. Analysis of brain sections through the striatum
obtained from individuals that died withMSA-P and control cases
showed preferential loss of the matrix marker, calbindin-D28k,
and maintenance of a striosome immunomarker in the individ-
uals with MSA-P (Goto and Hirano, 1990; Ito et al., 1992; Sato
et al., 2007). It was suggested that, in MSA-P, there is selective
loss of matrix MSNs in early stages of disease that progresses to
loss of MSNs in both compartments by late stages of disease (Sato
et al., 2007). Early loss of matrix signaling in MSA-P is consis-
tent with the course of dopamine terminal loss in more common
forms of PD, in which terminal loss progresses forward from the
caudal putamen, which is relatively poor in striosomes (Graybiel
and Ragsdale, 1978).
Considering the heterogeneity of PD-related disorders, it is
tempting to speculate that a consistent compartmentalized pat-
tern of dopamine terminal degenerationmight be found if patients
were classiﬁed according to detailed symptomatology, as has been
reported for HD (Tippett et al., 2007; Rosas et al., 2008; Thu
et al., 2010). As we discuss in the following section, the best evi-
dence to date for the status of striosomes and matrix in PD brains
comes from work on the expression of preproenkephalin opioids
in post-mortem sections from PD brains. In these, striosomes are
clearly preserved and over-activated in the brains of patients who
experienced dyskinesias as side effects of treatment (Henry et al.,
2003).
L-DOPA-INDUCED DYSKINESIAS
The most widely available treatment for PD is dopamine replace-
ment therapy by oral administration of the dopamine precursor,
l-3,4-dihydroxyphenylalanine (l-DOPA). However, as the dis-
ease progresses and the dopamine depletion becomes increasingly
more severe, l-DOPA treatment often produces debilitating invol-
untary movements referred to as LIDs. LIDs are likely evoked, at
least in part, by hyper-responsivity of MSNs to pulsatile dopamine
receptor stimulation during ongoing corticostriatal activation of
glutamate receptors (Jenner, 2008). Thus, treatment for these
side effects typically requires reducing the l-DOPA dosage to
suboptimal levels.
In rodent and non-human primate models, the occurrence of
LIDs is correlated with activation of both D1 and D2 dopamine
receptors and hyperactivation of the pro-movement direct path-
way (Gerfen et al., 1995, 2002, 2008; Jenner, 2008; Berthet et al.,
2009; Meurers et al., 2009; Cenci and Konradi, 2010). Stimula-
tion of D1 and glutamate receptors leads to the activation of
two key protein kinase cascades, denoted by their central kinase
mediators: PKA and ERK1/2 (Figure 2). D1 is known to sig-
nal through G-protein coupled receptors to activate adenylyl
cyclase for the generation of cAMP. cAMP, in turn, activates PKA,
which site-speciﬁcally phosphorylates the dopamine and cAMP-
regulated phosphoprotein 32 kDa (DARPP-32). DARPP-32 inter-
sects with the ERK1/2 cascade by blocking protein phosphatases
that would normally deactivate ERK1/2 (Valjent et al., 2005; San-
tini et al., 2007). PKA and ERK1/2 control chromatin remodeling
and phosphorylate the CREB and ELK transcription factors that
converge to drive expression of numerous IEGs, including, for
example, c-Fos (Valjent et al., 2005; Santini et al., 2007, 2009). The
induction of numerous IEGs has been observed in D1-positive
MSNs in normal animals treatedwith dopamine receptor agonists,
and this induction is dramatically increased in the dopamine-
depleted striatum of animals treated with l-DOPA (Valjent et al.,
2005; Santini et al., 2007,2009). Protein translation is also activated
in D1-positive MSNs of animal models of LIDs, via activation of
mammalian target of rapamycin (mTOR) and ERK1/2 (Santini
et al., 2009). Several studies indicate that in models of LIDs, there
is a switch from PKA- to ERK1/2-mediated signaling in driving
IEG expression (Andersson et al., 2001; Gerfen et al., 2002). Nev-
ertheless, inhibition of ERK1/2, PKA, or mTOR in the striatum
attenuates the development of LIDs in animal models (Gerfen
et al., 2002;Westin et al., 2007; Darmopil et al., 2009; Santini et al.,
2009; Lebel et al., 2010). The wide-spread expression and func-
tions of ERK1/2, PKA, and mTOR make them poor targets for
therapeutic intervention, however. Evidence from IEG induction
assays in human and animal models suggests that there is a strio-
some to matrix imbalance in signaling cascades that parallels the
development of LIDs. Strikingly striosome-predominant increases
in the expression of prodynorphin (also called preproenkephalin
B) have been documented in post-mortem striatal sections from
parkinsonian humans with LIDs (Henry et al., 2003). In monkeys,
the IEG Nur77 is dysregulated in striosomes following dopamine
depletion with and without dopamine replacement treatments
(Mahmoudi et al., 2009). In the anterior caudate nucleus of mon-
keys with dopamine depletion only, Nur77 is down-regulated
in striosomes, relative to levels in control monkeys. By con-
trast, following dopamine depletion with subsequent l-DOPA
treatment, Nur77 is strongly up-regulated in striosomal neurons.
The degree of Nur77 up-regulation is inversely correlated with
the severity of the LIDs, suggesting that the Nur77 modulation
is compensatory. Striosome-predominant IEG induction is also
observed in the dopamine-depleted striatum, relative to control
striatum, in rat models of LIDs (Cenci et al., 1999; Saka et al.,
1999).
This heightened IEG activity in striosomes may be related
to activation of the striosome-speciﬁc pathway to the SNc
(Figure 1B) or to the predominance of D1-positive neurons in
striosomes of some species, relative tomatrix (Table 1). These pos-
sibilities have not beendirectly assessed,but gene induction studies
show increased IEG expression in D1-positive neurons, relative
to changes in D2-positive neurons, in rat models of LIDs (Ger-
fen, 2003; Santini et al., 2009; Bateup et al., 2010). Furthermore,
there may be increased signal transduction from D1 receptors in
striosomes in LIDs, considering that Gαolf, the G-protein that
is coupled to the D1 receptor, is elevated in post-mortem tis-
sue from individuals who died with a diagnosis of PD (Corvol
et al., 2004). Gαolf is enriched in striosomes in normal mice (Sako
et al., 2010). An imbalance in striosome to matrix activity may
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also be related to the ﬁnding that selective antagonists of mu opi-
oid receptors dramatically reduce LIDs in non-human primate
models (Koprich et al., 2011). Mu opioid receptor activation con-
tributes to differential activation of striosomes overmatrix (Miura
et al., 2007), but whether mu opioid receptor antagonists reduce
excessive striosome to matrix activity in LIDs has not yet been
reported.
Increasing evidence suggests that ERK1/2-mediated IEG induc-
tion in LIDs may involve the striosome-enriched gene, CalDAG-
GEFII (Kawasaki et al., 1998; Dower et al., 2000; Pierret et al.,
2002; Crittenden et al., 2009). CalDAG-GEFII, an ERK1/2 acti-
vator, is strongly up-regulated in a rat model of LIDs, and has
a striking striosome-enriched pattern. By contrast, the matrix-
enriched gene, CalDAG-GEFI, is down-regulated in the same
model. The dysregulation of both of these genes was found to
occur in proportion to the severity of LIDs that were expressed
premortem in rats (Crittenden et al., 2009). Genetic deletion of
another ERK1/2 activator, Ras-GRF1, partially alleviates the devel-
opment of LIDs in a mouse model, and combined Ras-GRF1 and
ERK1/2 knockdown reduces LIDs in a monkey model (Fasano
et al., 2010). LIDs are further reduced in the Ras-GRF1 knock-
out mice by treatment with doses of ERK1/2 antagonists that are
too low to be effective in control mice. These results suggest that
there are multiple pathways to ERK1/2 activation in LIDs and that
Ras-GRF1 and CalDAG-GEFII might, together, fully activate this
pathway.
Recent studies highlight evidence that ERK1/2 activation in
MSNs is high in the early stages of LIDs induction but decreases
with prolonged treatment, despite the maintenance of the dysk-
inetic behaviors (Santini et al., 2010; Ding et al., 2011). By con-
trast, striatal DARPP-32 phosphorylation is highest in dopamine-
depleted animals that received prolonged l-DOPA treatment.
These results led to the proposal that ERK1/2 cascades are
important for the priming that constitutes excessive responses of
dopamine-depleted animals to the ﬁrst-ever l-DOPA treatment,
whereas cAMP/PKA/DARPP-32 signaling cascades are important
for the maintenance of LIDs. However, activated ERK1/2 has been
found in cholinergic interneurons of parkinsonian rodent models
after prolonged l-DOPA treatment, indicating that ERK1/2 may
be critical in MSNs for LID priming and in a sparsely distributed
striatal interneuron for LID maintenance (Ding et al., 2011).
Taken together, this evidence strongly suggests that MSNs in
striosomes are over-activated, relative to matrix MSNs, in LIDs.
This differential activation is likely related to PKA and ERK1/2
activation in striatalMSNs (likely involving theCalDAG-GEFs and
Ras-GRF1), and in striatal cholinergic interneurons. Strikingly,
increased IEG activation of striosomes relative to matrix is also
evoked by over-stimulation of the dopamine system with drugs of
abuse. Such over-stimulation elicits repetitive motor and cogni-
tive behaviors that share features with LIDs that are observed in a
subpopulation of individuals with PD (Voon et al., 2009). There
is a strong and direct correlation between the severity of repetitive
behaviors induced by dopamine receptor agonists and the ratio of
striosome to matrix IEG up-regulation, further suggesting a link
between these different hyper-kinetic states (Canales andGraybiel,
2000; Graybiel et al., 2000).
DYSTONIA
Dystonia presents as twisting limbmovements or sustained abnor-
mal body postures that are attributed to failures in motor control
and sensory integration by the cortico-basal ganglia-thalamic loop
(Kaji et al., 2005). Electromyographic recordings from the mus-
cles of patients with dystonia have shown that, during a dystonic
event, there is co-contraction of opposing muscles or activation of
muscle groups neighboring those that are normally used (Cohen
and Hallett, 1988; Fahn, 1989). Dystonia can appear in childhood
or in adulthood and can involve a single body part (focal), a group
of adjacent body parts (segmental) or the whole body (gener-
alized). As with PD, the susceptibility to disease genes and risk
factors is variable (Roze et al., 2009; Schmidt et al., 2009). Dys-
tonia can be evoked by a wide variety of phenomena, including
repetitive motor tasks, anti-psychotic medications, brain damage,
environmental factors, neurological disease (e.g., PD andHD) and
genetic mutations. Intense repetition of a speciﬁcmotor task, such
as playing a musical instrument or typing, can predispose indi-
viduals to focal dystonias, including writer’s cramp (Byl et al.,
1996; Roze et al., 2009). In a review of 158 hemidystonia cases
involving stroke, head trauma, or perinatal hypoxia as precipitat-
ing factors, 60% were found to have lesions in the contralateral
striatum (Chuang et al., 2002). However, disruptions to the stria-
tum, neocortex, GPi, VTA, thalamus, cerebellum, and brain stem
can all produce forms of dystonia-like symptoms in animalmodels
(Guehl et al., 2009). Dystonia is also associated with complications
of childbirth (Bressman, 2000), presumably because of the hyper-
sensitivity of the neonatal basal ganglia to hypoxia. The latency
between the precipitating event and the onset of dystonia is often
months to years, supporting the hypothesis that aberrant neuro-
plasticity in the striatum and/or neocortex contributes to dystonia
(Byl et al., 1996; Quartarone et al., 2003; Peterson et al., 2010). Dis-
organization of the somatotopy in the somatosensory and motor
cortices and in the basal ganglia has been observed in dystonia
(Lenz et al., 1998; Vitek et al., 1999; Quartarone et al., 2008; Del-
maire et al., 2009; Tamura et al., 2009). This may bear relevance
to the fact that touching a body region near the affected mus-
cle groups can sometimes alleviate symptoms – a long-recognized
phenomenon referred to as a “sensory trick.”
Given the heterogeneity in the etiology of dystonia, it is to be
expected that there are multiple cellular signaling abnormalities.
However, there is a scarcity of reports on signaling mechanisms
in dystonia, relative to the many such studies in models of PD,
LID, and HD. Dopamine and acetylcholine signaling are known
to be important in several forms of dystonia. The clearest exam-
ple of this is dopamine-responsive dystonia (DRD; also known
as Segawa’s disease or DYT5). DRD is an autosomal dominant
genetic disorder that is usually produced by loss of functionmuta-
tions inGTP cyclohydrolase 1 (GCH1; Ichinose et al., 1994; Ludecke
et al., 1996; Thony and Blau, 1997, 2006). GCH1 is in the pathway
for synthesis of tetrahydrobiopterin (BH4), an essential cofactor
for the dopamine-synthesizing protein, TH. Therefore, in DRD,
there is likely a deﬁciency in dopamine, and related biogenic
amines, throughout development. Age of onset is variable but
often early, and symptoms range from focal to generalized dysto-
nia to developmental delay (Segawa, 2011).Many of the symptoms
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are alleviated by l-DOPA administration, and LIDs are typically
not a complication.
Loss of dopamine in adulthood is also associated with dys-
tonia, as a secondary symptom of PD. In addition, the classical
anti-psychotic medications that antagonize D2 receptor signaling
precipitate acute or tardive dystonia in a signiﬁcant proportion of
patients and in animal models (Kiriakakis et al., 1998). Moderate
abnormalities in D2 receptor binding and expression are observed
in cases of focal and generalized dystonia (Tanabe et al., 2009), but
whether the defects are in post-synaptic D2 receptors onMSNs, in
presynaptic D2 autoreceptors that inhibit dopamine release or in
D2-positive striatal interneurons remains controversial (Playford
et al., 1993; Naumann et al., 1998; Napolitano et al., 2010).
Dopamine and acetylcholine signaling are tightly interrelated
in the striatum and anticholinergic drugs improve dystonic symp-
toms in some patients and animalmodels (Bressman, 2000). Clues
to the relevance of acetylcholine signaling in dystonia come from
animal models of DYT1. DYT1 is produced by a mutation in
torsinA (Ozelius et al., 1997), which is expressed widely but is
enriched in the cholinergic interneurons of the striatum (thought
to correspond mainly to the physiologically identiﬁed tonically
active neurons, or TANs) and in dopaminergic neurons of the SNc
(Shashidharan et al., 2000; Oberlin et al., 2004). D2 is expressed
in cholinergic interneurons and can, under certain conditions,
inhibit their activation and thereby permit long-term depression
(LTD) in MSNs (Wang et al., 2006b). However, in slice record-
ings from the mouse model of DYT1, the effect is reversed such
that D2 agonists activate cholinergic interneurons and MSNs fail
to undergo LTD (Pisani et al., 2003). This failure of MSN neu-
roplasticity is rescued by blocking acetylcholine receptors. Thus,
anticholinergics may serve to restore normal plasticity of MSNs in
DYT1models. Because cholinergic interneurons control striosome
to matrix activity ratios (Saka et al., 2002), it is possible that anti-
cholinergic therapies change the communication between these
striatal compartments as well.
The most direct case made for a striosome to matrix imbal-
ance in some types of dystonia comes from post-mortem analy-
ses of striatal tissue from individuals with X-linked dystonia-
parkinsonism (DYT3). DYT3 is caused by mutations in the tran-
scription factor TAF1 and manifests as adult-onset dystonia, often
generalized, that progresses to parkinsonism (Makino et al., 2007).
Histological analyses of post-mortem striatal sections from ﬁve
people with DYT3 who died during the dystonic phase and two
people who died during the parkinsonian phase led to the dis-
covery of severe striosome degeneration in the individuals with
dystonia (Goto et al., 2005). Analyses suggested that gliosis and
MSN loss is conﬁned to the striosomal compartment in the indi-
viduals in the dystonic phase whereas MSN degeneration spreads
to both compartments in the individuals in the parkinsonianphase
of the disease. Striatal projections into the GPi, GPe, and substan-
tia nigra all appear to be signiﬁcantly depleted in a presentedDYT3
case. TH staining for dopaminergic neurons in the substantia nigra
was patchy, suggesting that there was also ventralmidbrain pathol-
ogy. Thus, DYT3 appears to cause degeneration of MSNs in the
striosome compartment in the early phase of the disease and then
progresses to cause degeneration of MSNs in the matrix compart-
ment as well. This preferential loss of striosomal MSNs ﬁts with
the expression of N-TAF1, the neuron-speciﬁc isoform of TAF1
that is implicated as causative in DYT3. In the rat, N-TAF1 expres-
sion is strikingly enriched in striosomal MSNs, relative to the low
expression in the extra-striosomal matrix (Sako et al., 2011).
Support for the possibility that striosomes are differentially
affected in other forms of dystonia comes from a mouse model
of an unusual form of DRD. To generate this mouse line, a muta-
tion was introduced into 6-pyruvoyl tetrahydropterin synthase,
an enzyme that is required for BH4 synthesis and that was found
to be mutated in a human case of DRD (Hanihara et al., 1997).
These mutant mice exhibit abnormal hindlimb clasping and slow
beam-crossing behavior, suggestive of dystonic and parkinson-
ian symptoms. A postnatal, striosome-predominant loss of TH
protein is observed. The pattern of TH depletion also exhibits
similarities to that observed in PD in that it was depleted in a
caudal-to-rostral gradient andpreserved in thenucleus accumbens
(Sato et al., 2008). Unlike in PD however, this DRD mouse model
shows preservation of SNc integrity, based on immunostaining
of brain sections for markers of dopaminergic neurons. Thus, it
appears that 6-pyruvoyl tetrahydropterin synthase is required for
TH expression in the terminals of dopaminergic neurons targeting
the striosomes, suggesting that preferential dopamine loss in the
striosomes may occur in DRD. Clinical studies have yet to test this
idea, however.
DRUG ADDICTION
Drug addiction is generally agreed to involve the repeated and
escalating use of psychoactive drugs, despite adverse consequences
such as loss of employment, friends, and family ties (Diagnostic
and Statistical Manual of Mental Disorders IV). Only ∼15% of
people and animals who experience a highly addictive drug esca-
late their use to the point of addiction (Deroche-Gamonet et al.,
2004). Susceptibility to drug addiction has environmental com-
ponents (in particular, repeated drug administration) and genetic
components. Twin studies suggest that as much as 50% of the
susceptibility may be genetic (Kreek et al., 2005). Relapse after
withdrawal is associated, in both humans and animalmodels, with
stress, re-exposure to the drug, or re-exposure to environmental
cues associated with the drug (Sinha, 2008). Cues and experiences
that promote reinstatement of drug use can activate the same brain
regions as the drugs themselves, suggesting that they share neuro-
circuitry and underlying molecular mechanisms (Childress et al.,
1999; Volkow et al., 2006).
It is widely agreed that there are differential effects of drugs of
abuse on signaling pathways in the ventromedial and dorsolateral
striatum, in the direct and indirect pathways, and in striosome and
matrix compartments. Human brain imaging studies have shown
that acute drug exposure activates limbic structures including the
nucleus accumbens and amygdala and that repeated use expands
the region of activation to include the dorsal striatum and neocor-
tex (Breiter et al., 1997; Volkow et al., 2006; Porrino et al., 2007).
This changing pattern of activation might be related to the change
in self-reported effects of the drug: in the early phases, individuals
describe hedonic effects of the drug but in late phases of addic-
tion the effects are more likely to be described as “ﬁlling a hole”
(Robinson and Berridge, 2008). This contrast ﬁts with the notion
that the ventromedial striatum and nucleus accumbens mediate
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goal-oriented behaviors (e.g., early, hedonia-seeking drug use)
whereas the dorsolateral striatum and some neocortical regions
mediate habitual behaviors (e.g., late, compulsive drug use; Yin
et al., 2004; Barnes et al., 2005; Atallah et al., 2007). Considering
that drugs of abuse and associated cues activate the dopamine sys-
tem (Di Chiara and Imperato, 1988), the transition from ventral to
dorsal striatum activity with repeated drug use may be inﬂuenced
by indirectly recursive corticostriatal circuitry and an apparently
progressive connectivity of the striatonigral loop (Haber et al.,
2000; Ikemoto, 2007). This possibility has been supported by stud-
ies in rats in which physical disruption of this ventral to dorsal
striatal connectivity pattern was shown to interfere with the devel-
opment of habitual responding for drug access (Belin and Everitt,
2008). Thus, the development of a drug-taking habit may rely on
the dorsal striatum,andother brain regions, that normallymediate
the acquisition of motor and cognitive habits.
Locomotor and highly repetitive and idiosyncratic motor
behaviors (stereotypies) are elicited in humans and animals
under the inﬂuence psychomotor stimulants such as cocaine and
amphetamine. These motoric responses to drugs of abuse escalate
with repeated treatments, a phenomenon that is termed sensiti-
zation and that is thought to be related to drug addiction (Vezina
and Leyton, 2009). There is strong evidence that both PKA and
ERK1/2 cascades in MSNs mediate acute and sensitized responses
to psychomotor stimulants (Ferguson and Robinson, 2004; Shi
andMcginty, 2006; Girault et al., 2007; Russo et al., 2010). Genetic
deletion of DARPP-32 (a key effector of the PKA cascade) and
inhibitors of MEK1 (an upstream activator of ERK1/2) each block
sensitization to drugs of abuse (Valjent et al., 2005). Immuno-
histochemistry for phosphorylation of activating sites on various
members of the PKA and ERK1/2 cascades show that drugs of
abuse activate these cascades primarily in D1-expressing neurons
(Valjent et al., 2005; Bertran-Gonzalez et al., 2008). Likewise,Delta
FosB, an IEG that is downstream of both signaling cascades, is
activated preferentially in D1-expressing neurons following drug
treatments (Berretta et al., 1992; Hope et al., 1994; Moratalla
et al., 1996; Zachariou et al., 2006; Fasano et al., 2009). Acti-
vation of D2-positive MSNs is not observed in most reports of
MSN activation by drugs of abuse (Bertran-Gonzalez et al., 2008),
but this ﬁnding may depend on the context in which the drug is
taken, given that the activation of D2-positive MSNs is observed
when drugs are administered in a novel cage (Badiani et al., 1999;
Ferguson and Robinson, 2004; Vezina and Leyton, 2009). Further-
more, it is widely recognized that normal acute and sensitized
responses to drugs of abuse are dependent on both D1- and D2-
type dopamine receptor activation (Xu et al., 1994; Caine et al.,
2002, 2007; Capper-Loup et al., 2002; Barrett et al., 2004; Bateup
et al., 2010). Pharmacologic or genetic studies indicating a D2-
dependence of drug responses do not typically specify the cell-type
of action. Therefore, it may be that D2 activity is required in
non-MSN cell types such as cholinergic interneurons, which are
sparsely distributed in the striatum. Cholinergic interneurons are
implicated in the development of LIDs (Ding et al., 2011) and are
required for the increased striosome over matrix activity ratios
associated with drugs of abuse (Saka et al., 2002). Psychomotor
stimulants have also been shown to signal through D1/D2 het-
erodimers (Perreault et al., 2010). Thus, D2 expression in MSNs,
striatal interneurons, dopamine-producing axon terminals, and
D1/D2 heteromers may all be important for particular aspects
of drug responsivity. Histochemical examination of post-mortem
brains from cocaine addicts who tested positive for cocaine at
autopsy, showed that mRNA for dynorphin was selectively ele-
vated in striosomes in the caudate nucleus (Hurd andHerkenham,
1993). In animal models, strong behavioral responses to psy-
chomotor stimulants, administered by intraperitoneal injection in
the home cage, is correlated with a profound change in IEG induc-
tion in the striosome vs. matrix compartments, favoring increased
activation in striosomes (Graybiel et al., 1990b; Canales and Gray-
biel, 2000; Vanderschuren et al., 2002; Glickstein and Schmauss,
2004; Saka et al., 2004). At very high doses, or with repeated treat-
ments, psychomotor stimulants suppress locomotion in favor of
a limited number of spatially conﬁned stereotypies (Lyon and
Robbins, 1975). In rats and monkeys, there is a direct correla-
tion between the intensity of drug-induced stereotypy and the
increased striosome to matrix ratio of IEG induction in the dor-
solateral quadrant of the striatum (Canales and Graybiel, 2000;
Saka et al., 2004). Based on this correlation, it was suggested that
increased striosome activity and repressed matrix activity in this
zone, together, could predict the degree of repetitive behavior
expressed. The possibility that increased activity in the striosomes
promotes stereotypies whereas activity in the matrix permits ﬂex-
ibility in motor behaviors is consistent with several additional
studies. First, rats with a self-stimulation electrode implanted in
or near a striosome learn to bar-press more frequently for stim-
ulation than rats in which the stimulating electrode is implanted
in the matrix (White and Hiroi, 1998). Second, metabolic label-
ing studies show that rats moving freely or under gentle restraint
in their home cage have preferential activation of MSNs in the
matrix compartment (Brown et al., 2002). Third, knockout mice
that lack CalDAG-GEFI, an ERK1/2 regulator that is selectively
enriched in the matrix compartment, show enhanced stereotypy
responses to amphetamine, relative to sibling controls (Crittenden
et al., 2006). Importantly, the CalDAG-GEFI knockout mice have
normal locomotor responses to low doses of amphetamine, and
locomote normally in the absence of drug, suggesting that disrup-
tion of matrix function speciﬁcally promotes stereotypies induced
by high doses of amphetamine. The possibility that differential
signaling in the striosomes vs. matrix is related to the switch from
goal-oriented behavior to habitual, goal-independent behaviors
that compare to drug-induced stereotypy is reviewed by Canales
(2005).
Vanderschuren et al. (2002) showed that increased striosome to
matrix activity was also observed in adult rats treated with a single
high dose, or with repeated low doses, of amphetamine and sug-
gested that the compartmental ratio change was correlated with
overall drug response rather than speciﬁcally with stereotypies.
However, this study did not rate stereotypic behaviors and even
low doses of stimulant drug can induce intermittent stereotyp-
ies such as snifﬁng. A single high dose of methylphenidate, an
indirect dopamine receptor agonist that is prescribed to children
for ADHD, also induces preferential IEG expression in striosomes
of adolescent mice (Davis and Puhl, 2011). In follow-up cell cul-
ture studies, methylphenidate appeared to be acting through D1
and cAMP-mediated signaling cascades, which are enriched in
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striosomes (Davis and Puhl, 2011). Likewise, in a study of spon-
taneous stereotypies in deer mice, it was found that there is an
increase in direct over indirect pathway activity, relative to non-
stereotypic controls (Tanimura et al., 2011). The stereotypic deer
mice do not show changes in striosome to matrix activity, as mea-
sured by cytochrome oxidase histochemistry, however. Together,
these studies indicate that an increased striosome to matrix activ-
ity ratio is correlated with hyper-responsivity to psychomotor
stimulants.
Although one study found that deletion of a matrix-enriched
signaling molecule (CalDAG-GEFI) is sufﬁcient to promote drug-
induced stereotypies (Crittenden et al., 2006), other studies show
that an increase in striosome tomatrix IEG activity is not necessary
to elicit stereotypy. In rats, ablation of cholinergic and nitric oxide
synthase-positive interneurons prevents the compartmentalized
IEG induction ratio, but not the sensitization of drug-associated
stereotypies (Saka et al., 2002). Additionally,mice lackingD2 show
increased stereotypy responses toD1-type dopamine receptor ago-
nists but do not exhibit increased striosome to matrix ratios of
IEG induction (Glickstein and Schmauss, 2004). By contrast,mice
with striosome, but not matrix, overexpression of the negative
mGluR1/5 modulator, Homer1a, show enhanced locomotor and
stereotypy responses to amphetamine (Tappe and Kuner, 2006).
These mice may not have decreased mGluR1/5 signaling how-
ever, as they show strong and patchy (presumably striosomal) IEG
induction in the striatum. Evidence that there is not a simple
correlation between increased striosome function and increased
responses to drugs of abuse comes from mice in which rostral
striosomes fail to develop (Liao et al., 2008). Mice lacking RARβ,
a transcription factor that is required for formation of rostral
striosomes, exhibit enhanced repetitive behavioral responses to
apomorphine. At a dose of apomorphine that does not affect
behaviors of control mice, mice lacking RARβ show increased
stereotypic responses. These results could be interpreted to indi-
cate that increased striosome to matrix activity normally serves to
dampen stereotypies.Alternatively, any striosome tomatrix imbal-
ance, regardless of direction, might predispose to drug-induced
stereotypies. In addition, how the selective disruption of strio-
some or matrix function inﬂuences behavioral responses to drugs
of abuse could depend on the context of drug exposure and which
region of the striatum is activated. This apparent complexity is
not surprising considering that different drugs of abuse induce
distinct patterns of striosome and matrix IEG induction across
the caudal–rostral and medial–lateral gradients of the striatum,
and that there are differences in the connectivity and transmit-
ter/modulator expression patterns of the striosomes themselves
in different striatal regions (Graybiel et al., 1990b; Hurd and
Herkenham, 1993;Wang et al., 1994; Tan et al., 2000; Adams et al.,
2001).
Repeated treatment of rats with drugs of abuse also activates
IEG expression in the cholinergic interneurons that reside at the
compartment borders (Moratalla et al., 1996). This ﬁnding is likely
related to the observation that prolonged l-DOPA treatment of PD
models induces ERK activation in cholinergic interneurons (Ding
et al., 2011). Moreover, pharmacological disruption of choliner-
gic signaling modulates stereotypy responses to drugs of abuse
with a dependence on medial–lateral striatal gradients (Ohmori
et al., 1995; Aliane et al., 2011). Ablation of cholinergic interneu-
rons disrupts the increased striosome to matrix activity ratio in
response to the direct dopamine receptor agonist, apomorphine
(Saka et al., 2002). The CalDAG-GEFI knockout mice that have
exaggerated drug-induced stereotypies have defective cholinergic
signaling as well (Crittenden et al., 2006). Thus, cholinergic mod-
ulation of drug responses may occur, in part, through control of
striosome to matrix activity ratios.
Studies in animalmodels suggest that the striosome andmatrix
compartments are differentially vulnerable to the loss of dopamine
terminals that is caused by drug abuse. Treatment of mice with
high doses of either methamphetamine or MDMA (“ecstasy”)
causes selective degeneration of dopaminergic inputs to the strio-
somes, relative to the surrounding matrix (Granado et al., 2008,
2010). This selective vulnerability was suggested to be related
to the relatively lower striosomal levels of superoxide dismu-
tase 2 (SOD2; Zhang et al., 1994; Medina et al., 1996), which
neutralizes the reactive oxygen species that are a byproduct of
dopamine metabolism. Another possibility is that the enriched
vascularization of striosomes (Breuer et al., 2005) causes them to
have increased exposure to injected drugs. Striosomal immuno-
markers are selectively depleted in rats treated with excitotoxic
drugs or that undergo neonatal hypoxia (Burke and Baimbridge,
1993; Figueredo-Cardenas et al., 1998). The anti-apoptosis fac-
tor, Bcl-2, and the neurotrophic factor, GDNF, are enriched in
striosomal neurons, suggesting that they may have compensatory
anti-neurodegenerationmechanisms in place (Bernier and Parent,
1998; Lopez-Martin et al., 1999;Oo et al., 2005). There remain only
a few cases inwhich brains of drug abuserswere processed to detect
striosomes, and cell death was not assayed in this study, but the
selective striosomal enhancement of the opioid, dynorphin, could
relate to striatum-based disruption of limbic-related behaviors in
addition to effects attributable to the ventral striatum itself (Hurd
and Herkenham, 1993).
In summary, normal and dopamine-depleted animals show
a strong correlation between the degree of striosome to matrix
ratio of MSN activation and the degree of behavioral response to
dopamine agonists or drugs of abuse. New genetic tools that allow
the speciﬁc activation or repression of genes in deﬁned subsets of
striosomal and matrix MSNs will allow us to better understand
the meaning of this correlation.
CONCLUSION
Striosomes are heavily innervated by limbic cortices,whichmay be
related to the preferential degeneration of striosomes and cingu-
late cortex in individuals withmood disorders associatedwithHD.
Striosomes are also implicated in limbic control of motor behav-
iors based on ﬁndings that drug addicts and suicide victims exhibit
preferentially increased striosomal expression of prodynorphin,
relative to control individuals. Evidence for imbalance between
striosome and matrix functions in PD is primarily associated
with l-DOPA treatment that can produce dyskinesias. In some
individuals, LIDs are associated with mood disruptions and com-
pulsive behaviors that resemble behaviors seen in drug addicts.
Animal models and a few clinical studies support the idea that
there are similarities between the excessive dopamine signaling
that occurs in MSNs of individuals with LIDs and in drug abuse.
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Hyperactivation of D1-positive MSNs and increased striosome to
matrix activity ratios have been observed in models of both dis-
orders. Inhibitors of PKA and ERK signaling can alleviate LIDs
and drug sensitization but more speciﬁc targets are needed for
therapeutic development. Dystonic symptoms of rigidity can co-
occur with the basal ganglia disorders of HD, PD, and LIDs and
several small clinical studies indicate differential degeneration of
striosome vs. matrix MSNs in hereditary forms of dystonia. The
striosome-speciﬁc pathway to the SNcmay be important for some
aspects of HD, LIDs, dystonia, and drug addiction, which have
overlapping symptoms of hyperactivation of the motor system
and mood disturbances.
Much remains to be determined about the relevance of
striosome–matrix architecture to human neurologic and neu-
ropsychiatric disorders. First and foremost, striosomes have so far
been below-threshold for reliable detection by human brain imag-
ing methods currently in use, so that evidence is restricted to rare
post-mortem specimens. Even in instances in which observations
have been made on human brains, they are necessarily incom-
plete. And importantly, even though there is mounting evidence
that some aspects of repetitive behaviormay be related to excessive
striosomal signaling, there are still no studies for some human dis-
orders in which repetitive behaviors are common symptoms, such
as in autism spectrum disorders. Technical advances are close to
overcoming some of these limitations, and promise insights into
the functions of the highly developed striosomal system of the
human striatum.
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